On Tuesday, Jefferies, a global investment banking firm, upgraded Relmada Therapeutics Inc (NASDAQ:RLMD) stock from Hold to Buy, significantly raising the price target to $13.00 from the previous $3.50. This adjustment comes as the company anticipates a potential turnaround with its Phase III interim analysis for REL-1017, a novel depression treatment, expected by the end of 2024.
The analyst at Jefferies suggests that the previous failures of REL-1017 in two Phase III trials were likely due to execution errors leading to a high placebo effect, rather than an inherent lack of efficacy in the drug itself. With the upcoming interim analysis, there is a belief that the study could reveal a positive outcome for REL-1017.
According to the analyst, the interim results have the potential to significantly impact the company's valuation. If the study proceeds as hoped, there could be a 5 to 10 times upside in the stock's value. Conversely, if the interim analysis indicates futility, or a failure of the drug, the stock could see a decline of 50 to 80 percent.
The investment firm's decision to upgrade Relmada Therapeutics to a Buy rating is based on what they consider a favorable risk/reward setup. The current market capitalization of around $100 million is seen as an attractive entry point for investors, given the possible outcomes of the upcoming clinical trial interim analysis.
Relmada Therapeutics is focused on developing novel therapies for the treatment of central nervous system (CNS) diseases, with REL-1017 as their lead candidate for major depressive disorder. The market for depression treatments is substantial, with the analyst noting the drug's potential to reach over $1 billion in sales if successful.
In other recent news, Relmada Therapeutics has made significant progress in its clinical trials. The company is nearing the completion of its Phase 3 program for REL-1017, a drug candidate for major depressive disorder (MDD). Relmada plans to submit a New Drug Application (NDA) for this drug by the end of 2024. Furthermore, the company has initiated a Phase 1 study for REL-P11, a promising candidate for treating metabolic diseases.
Mizuho Securities recently sustained its Outperform rating and $25.00 stock price target for Relmada, following insider share purchases by key company executives. The firm interprets these purchases as indicative of confidence in the potential success of the upcoming interim analysis of the RELIANCE II trial.
Relmada's robust financial resources are projected to support its operations and key milestones through 2025. These recent developments demonstrate the company's commitment to advancing its clinical trials and expanding its treatment portfolio.
InvestingPro Insights
Relmada Therapeutics Inc (NASDAQ:RLMD) has garnered attention with its promising depression treatment, REL-1017, and an upgrade from Jefferies. In light of this, several InvestingPro Tips and real-time data provide additional context for investors considering RLMD's potential. Notably, the company holds more cash than debt, which may offer some financial flexibility in advancing its clinical programs. Additionally, RLMD has seen a significant return over the last week, with a 9.96% price total return, which aligns with the optimism surrounding the upcoming Phase III interim analysis.
However, it's important to note that analysts do not anticipate RLMD to be profitable this year, and the company has not been profitable over the last twelve months. With a market capitalization of approximately $91.43 million and a negative P/E ratio reflecting its current lack of earnings, the company's financial health hinges on the success of its lead candidate. The InvestingPro platform lists additional tips, which could further guide investor decisions regarding RLMD.
For those interested in a deeper dive, the InvestingPro platform includes more tips for RLMD, which could provide further insights into the company's prospects. For instance, RLMD's liquid assets exceed its short-term obligations, which could be a positive sign for its short-term financial stability.
In summary, while the potential for REL-1017 is a strong focus point, investors should consider the broader financial health and market performance of Relmada Therapeutics as they evaluate the company's long-term prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.